{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T13:52:20Z","timestamp":1764251540049,"version":"3.37.3"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,10,15]],"date-time":"2018-10-15T00:00:00Z","timestamp":1539561600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["03V0347"],"award-info":[{"award-number":["03V0347"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008791","name":"Bayer CropScience","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008791","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Gynecol Obstet"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1007\/s00404-018-4933-z","type":"journal-article","created":{"date-parts":[[2018,10,15]],"date-time":"2018-10-15T03:37:19Z","timestamp":1539574639000},"page":"211-216","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Mesothelin as a target for cervical cancer therapy"],"prefix":"10.1007","volume":"299","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5934-544X","authenticated-orcid":false,"given":"Korinna","family":"J\u00f6hrens","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5370-8163","authenticated-orcid":false,"given":"Lea","family":"Lazzerini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3813-9270","authenticated-orcid":false,"given":"Jana","family":"Barinoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5963-6623","authenticated-orcid":false,"given":"Jalid","family":"Sehouli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4500-8108","authenticated-orcid":false,"given":"Guenter","family":"Cichon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,10,15]]},"reference":[{"key":"4933_CR1","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1002\/ijc.2910500308","volume":"50","author":"K Chang","year":"1992","unstructured":"Chang K, Pastan I, Willingham MC (1992) Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium. Int J Cancer 50:373\u2013381","journal-title":"Int J Cancer"},{"key":"4933_CR2","doi-asserted-by":"publisher","first-page":"218","DOI":"10.4291\/wjgp.v7.i2.218","volume":"7","author":"T Einama","year":"2016","unstructured":"Einama T, Kawamata F, Kamachi H, Nishihara H, Homma S, Matsuzawa F et al (2016) Clinical impacts of mesothelin expression in gastrointestinal carcinomas. World J Gastrointest Pathophysiol 7:218\u2013222","journal-title":"World J Gastrointest Pathophysiol"},{"key":"4933_CR3","doi-asserted-by":"publisher","first-page":"2902","DOI":"10.1128\/MCB.20.8.2902-2906.2000","volume":"20","author":"TK Bera","year":"2000","unstructured":"Bera TK, Pastan I (2000) Mesothelin is not required for normal mouse development or reproduction. Mol Cell Biol 20:2902\u20132906","journal-title":"Mol Cell Biol"},{"key":"4933_CR4","first-page":"245","volume":"2","author":"Y Reiter","year":"1996","unstructured":"Reiter Y, Pastan I (1996) Antibody engineering of recombinant Fv immunotoxins for improved targeting of cancer: disulfide-stabilized Fv immunotoxins. Clin Cancer Res 2:245\u2013252","journal-title":"Clin Cancer Res"},{"key":"4933_CR5","doi-asserted-by":"publisher","first-page":"5144","DOI":"10.1158\/1078-0432.CCR-07-0869","volume":"13","author":"R Hassan","year":"2007","unstructured":"Hassan R, Bullock S, Premkumar A, Kreitman RJ, Kindler H, Willingham MC et al (2007) Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus IV infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res 13:5144\u20135149","journal-title":"Clin Cancer Res"},{"key":"4933_CR6","doi-asserted-by":"publisher","first-page":"3311","DOI":"10.1002\/cncr.28875","volume":"120","author":"R Hassan","year":"2014","unstructured":"Hassan R, Sharon E, Thomas A, Zhang J, Ling A, Miettinen M et al (2014) Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125. Cancer 120:3311\u20133319","journal-title":"Cancer"},{"key":"4933_CR7","first-page":"20","volume":"7","author":"R Hassan","year":"2007","unstructured":"Hassan R, Ebel W, Routhier EL, Patel R, Kline JB, Zhang J et al (2007) Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin. Cancer Immun 7:20","journal-title":"Cancer Immun"},{"key":"4933_CR8","doi-asserted-by":"publisher","first-page":"6132","DOI":"10.1158\/1078-0432.CCR-10-2275","volume":"16","author":"R Hassan","year":"2010","unstructured":"Hassan R, Cohen SJ, Phillips M, Pastan I, Sharon E, Kelly RJ et al (2010) Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers. Clin Cancer Res 16:6132\u20136138","journal-title":"Clin Cancer Res"},{"key":"4933_CR9","doi-asserted-by":"publisher","first-page":"5927","DOI":"10.1158\/1078-0432.CCR-14-0804","volume":"20","author":"R Hassan","year":"2014","unstructured":"Hassan R, Kindler HL, Jahan T, Bazhenova L, Reck M, Thomas A et al (2014) Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res 20:5927\u20135936","journal-title":"Clin Cancer Res"},{"key":"4933_CR10","doi-asserted-by":"publisher","first-page":"208ra147","DOI":"10.1126\/scitranslmed.3006941","volume":"5","author":"R Hassan","year":"2013","unstructured":"Hassan R, Miller AC, Sharon E, Thomas A, Reynolds JC, Ling A et al (2013) Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression. Sci Transl Med 5:208ra147","journal-title":"Sci Transl Med"},{"key":"4933_CR11","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1200\/JCO.2014.57.4244","volume":"33","author":"DT Le","year":"2015","unstructured":"Le DT, Wang-Gillam A, Picozzi V, Greten TF, Crocenzi T, Springett G et al (2015) Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J Clin Oncol 33:1325\u20131333","journal-title":"J Clin Oncol"},{"issue":"6","key":"4933_CR12","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1158\/1535-7163.MCT-13-0926","volume":"13","author":"S Golfier","year":"2014","unstructured":"Golfier S, Kopitz C, Kahnert A, Heisler I, Schatz CA et al (2014) Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect. Mol Cancer Ther 13(6):1537\u20131548","journal-title":"Mol Cancer Ther"},{"issue":"20","key":"4933_CR13","doi-asserted-by":"publisher","first-page":"3798","DOI":"10.1200\/JCO.2003.11.069","volume":"21","author":"FR Hirsch","year":"2003","unstructured":"Hirsch FR, Varella-Garcia M, Bunn PA Jr, Di Maria MV, Veve R, Bremmes RM et al (2003) Epidermal growth factor receptor in non-small-cell lung carcinaoms: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 21(20):3798\u2013807","journal-title":"J Clin Oncol"},{"key":"4933_CR14","doi-asserted-by":"publisher","first-page":"76","DOI":"10.2174\/2212697X03666160218215744","volume":"3","author":"XY Zhao","year":"2016","unstructured":"Zhao XY, Subramanyam B, Sarapa N, Golfier S, Dinter H (2016) Novel antibody therapeutics targeting mesothelin in solid tumors. Clin Cancer Drugs 3:76\u201386","journal-title":"Clin Cancer Drugs"},{"issue":"28","key":"4933_CR15","doi-asserted-by":"crossref","first-page":"46425","DOI":"10.18632\/oncotarget.17436","volume":"8","author":"L Tian","year":"2017","unstructured":"Tian L, Zeng R, Wang X, Shen C, Lai Y, Wang M et al (2017) Prognostic significance of soluble mesothelin in malignant pleural mesothelioma: a meta-analysis. Oncotarget 8(28):46425\u201346435","journal-title":"Oncotarget"},{"key":"4933_CR16","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1177\/030006051204000608","volume":"40","author":"Y Wang","year":"2012","unstructured":"Wang Y, Wang L, Li D, Wang HB, Chen QF (2012) Mesothelin promotes invasion and metastasis in breast cancer cells. J Int Med Res 40:2109\u20132116","journal-title":"J Int Med Res"},{"key":"4933_CR17","doi-asserted-by":"publisher","first-page":"e114900","DOI":"10.1371\/journal.pone.0114900","volume":"9","author":"G Tozbikian","year":"2014","unstructured":"Tozbikian G, Brogi E, Kadota K, Catalano J, Akram M, Patil S et al (2014) Mesothelin expression in triple negative breast carcinomas correlates significantly with basal-like phenotype, distant metastases and decreased survival. PLoS One 9:e114900","journal-title":"PLoS One"},{"issue":"4","key":"4933_CR18","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1158\/1078-0432.CCR-13-1862","volume":"20","author":"SS Kachala","year":"2014","unstructured":"Kachala SS, Bograd AJ, Villena-Vargas J, Suzuki K, Servais EL, Kadota K et al (2014) Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early-stage lung adenocarcinoma. Clin Cancer Res 20(4):1020\u20131028","journal-title":"Clin Cancer Res"},{"key":"4933_CR19","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12943-017-0633-8","volume":"16","author":"X He","year":"2017","unstructured":"He X, Wang L, Riedel H, Wang K, Yang Y, Dinu CZ et al (2017) Mesothelin promotes epithelial-to-mesenchymal transition and tumorigenicity of human lung cancer and mesothelioma cells. Mol Cancer 16:63","journal-title":"Mol Cancer"},{"key":"4933_CR20","doi-asserted-by":"publisher","first-page":"122","DOI":"10.4132\/jptm.2016.11.18","volume":"51","author":"SH Han","year":"2017","unstructured":"Han SH, Joo M, Kim H, Chang S (2017) Mesothelin expression in gastric adenocarcinoma and its relation to clinical outcomes. J Pathol Transl Med 51:122\u2013128","journal-title":"J Pathol Transl Med"},{"key":"4933_CR21","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.clbc.2013.05.001","volume":"13","author":"N Parinyanitikul","year":"2013","unstructured":"Parinyanitikul N, Blumenschein GR, Wu Y, Lei X, Chavez-Macgregor M, Smart M et al (2013) Mesothelin expression and survival outcomes in triple receptor negative breast cancer. Clin Breast Cancer 13:378\u2013384","journal-title":"Clin Breast Cancer"},{"key":"4933_CR22","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/jso.22024","volume":"105","author":"K Baba","year":"2012","unstructured":"Baba K, Ishigami S, Arigami T, Uenosono Y, Okumura H, Matsumoto M et al (2012) Mesothelin expression correlates with prolonged patient survival in gastric cancer. J Surg Oncol 105:195\u2013199","journal-title":"J Surg Oncol"},{"key":"4933_CR23","unstructured":"Bendell J, Blumenschein G, Zinner R, et al. (2016) First-in-human phase I dose escalation study of a novel anti-mesothelin antibody drug conjugate (ADC), BAY 94-9343, in patients with advanced solid tumors. In: Proceedings of the 104th annual meeting of the American 86 clinical cancer drugs 3; no. 2"},{"key":"#cr-split#-4933_CR24.1","unstructured":"Hassan et al. (2015) Phase I study of anti-mesothelin antibody drug conjugate anetumab ravtansine (ID 1574"},{"key":"#cr-split#-4933_CR24.2","unstructured":"oral presentation). In: 16th World Conference on Lung Cancer WCLC 2015 in Denver, Colorado, September 6-9, 20"}],"container-title":["Archives of Gynecology and Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00404-018-4933-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-018-4933-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-018-4933-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T02:09:04Z","timestamp":1605233344000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00404-018-4933-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,15]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["4933"],"URL":"https:\/\/doi.org\/10.1007\/s00404-018-4933-z","relation":{},"ISSN":["0932-0067","1432-0711"],"issn-type":[{"type":"print","value":"0932-0067"},{"type":"electronic","value":"1432-0711"}],"subject":[],"published":{"date-parts":[[2018,10,15]]},"assertion":[{"value":"6 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Cichon received grant monies from Bayer AG. Prof. Sehouli receives funding for studies in ovarian cancer and serves on the Advisory Board as a consultant for Bayer. The other authors have no conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}